类风湿关节炎临床实践中JAK抑制剂与生物改善病情抗风湿药的比较心血管安全性:瑞典观察性队列研究
在瑞典类风湿关节炎临床实践中,2016至2021年启动JAK抑制剂、TNF抑制剂或非TNF生物改善病情抗风湿药的患者队列显示,JAK抑制剂组主要急性心血管事件年龄性别标化发生率与TNF抑制剂组相似(0.88 vs 0.91每100人年),完全校正模型未显示JAK抑制剂较TNF抑制剂增加MACE风险(HR=0.71,95%CI 0.51至0.99)。
要点
- JAK抑制剂组MACE年龄性别标化发生率为0.88每100人年,TNF抑制剂组为0.91每100人年,两组相似。
- 完全校正后JAK抑制剂较TNF抑制剂的MACE风险比为0.71(95%CI 0.51至0.99),非TNF生物改善病情抗风湿药为0.98(95%CI 0.78至1.23)。
- 未发现该风险比随治疗启动后时间变化的证据。
核心结论
- 在瑞典当前临床实践中,未发现类风湿关节炎患者使用JAK抑制剂较TNF抑制剂心血管风险更高的证据。
研究设计与样本
- 观察性队列研究,基于瑞典风湿病质量登记处2016至2021年启动JAK抑制剂、TNF抑制剂或非TNF生物改善病情抗风湿药的类风湿关节炎患者,链接国家登记处随访至2022年。
- 共识别13492例启动JAK抑制剂、非TNF生物改善病情抗风湿药或TNF抑制剂治疗的类风湿关节炎患者,其中3037例启动JAK抑制剂者中观察到59例MACE事件。
主要发现
- JAK抑制剂组MACE年龄性别标化发生率为0.88每100人年,TNF抑制剂组为0.91每100人年,两组相似。
- 完全校正模型显示,与TNF抑制剂相比,JAK抑制剂的MACE风险比为0.71(95%CI 0.51至0.99),非TNF生物改善病情抗风湿药的风险比为0.98(95%CI 0.78至1.23)。
- 未发现该风险比随治疗启动后时间变化的证据;在心血管事件富集子集中观察到更高发生率但风险比相似。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To compare the incidence of cardiovascular (CV) events in rheumatoid arthritis (RA) treated with janus kinase inhibitors (JAKi), tumour necrosis factor inhibitors (TNFi), or other biological disease-modifying antirheumatic drugs (bDMARDs), in clinical practice, and to contextualise these findings by comparing to the Swedish RA population and general population at large. METHODS: Patients with RA initiating JAKi, TNFi and non-TNFi bDMARDs were identified in the Swedish Rheumatology Quality Register between 2016 and 2021. Through linkages to national registers, a cohort of patients with RA, general population comparators, as well as covariates and incident major acute CV event (MACE, including myocardial infarction, stroke and fatal CV events) were identified until 2022. Crude and age-sex standardised rates were calculated and HRs estimated from multivariable Cox regression models using TNFi as reference. RESULTS: We identified 13 492 patients with RA initiating a JAKi, non-TNFi bDMARD or TNFi treatment. Among 3037 JAKi-initiators, 59 MACE events were observed. The age-sex standardised rates for MACE were similar in the JAKi (0.88 per 100 person years) and TNFi (0.91) cohorts. Fully adjusted models showed no increased rate of MACE with JAKi (HR=0.71, 95% CI 0.51 to 0.99), or non-TNFi bDMARD (HR=0.98; 95% CI 0.78 to 1.23) in comparison to TNFi. We found no evidence that this HR changed over time since treatment initiation. In a CV-enriched subset, we observed higher rates but similar HRs. CONCLUSIONS: As used in present clinical practice in Sweden, we found no evidence that CV risk is higher with JAKis than TNFis in RA.
引用
- Bower H, Frisell T, di Giuseppe D, et al. Comparative cardiovascular safety with janus kinase inhibitors and biological disease-modifying antirheumatic drugs as used in clinical practice: an observational cohort study from Sweden in patients with rheumatoid arthritis. RMD Open. 2023. PMID: 37996125. doi:10.1136/rmdopen-2023-003630
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。